On April 20, 2026 Oxcia in a collaboration with SLU and Karolinska Institutet, reported that mitotic MTH1 inhibitor OXC-101 is investigated in a pilot clinical study in canine lymphoma and hemangiosarcoma. The early clinical results are presented by Dr. Kumar Sanjiv at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting 19-22 April, 2026. The title of the presentation is: "OXC-2101 (karonudib) in canine lymphoma and hemangiosarcoma: Safety, early efficacy and translational potential" (Poster Number 7913) and will be presented Wed 22 April 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, Oxcia, APR 20, 2026, View Source;utm_medium=rss&utm_campaign=oxc-101-as-a-novel-therapy-in-canine-blood-cancer-will-be-presented-at-aacr [SID1234664547])